Loading…

Successful Identification of Glycine Transporter Inhibitors Using an Adaptation of a Functional Cell-Based Assay

Glycine transporter (GlyT1) function is typically measured by radiolabeled glycine uptake using lysis methods or scintillation proximity assays (SPAs), which have limited throughput. This study shows the adaptation of the standard cell lysis method to a screening assay with improved throughput and a...

Full description

Saved in:
Bibliographic Details
Published in:SLAS discovery 2009-12, Vol.14 (10), p.1185-1194
Main Authors: Kopec, Karla, Jones, Bruce, Thomas, Jeffrey C., Spais, Chrysanthe, McKenna, Beth Ann, Saville, Lisa, Husten, Jean, Meyer, Sheryl, Ator, Mark, Duzic, Emir
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Glycine transporter (GlyT1) function is typically measured by radiolabeled glycine uptake using lysis methods or scintillation proximity assays (SPAs), which have limited throughput. This study shows the adaptation of the standard cell lysis method to a screening assay with improved throughput and assay characteristics. The assay takes advantage of the 384-well format, standard laboratory automation, and cryopreserved CHO-K1 cells stably overexpressing human GlyT1a transporter (CHO-K1/hGlyT1a) that were validated and banked in advance of screening. The assay was evaluated for the time course of glycine uptake, Km, Vmax, Z′ factor analysis, and IC50 value determination with reference GlyT1 inhibitors. Screening of 118,000 compounds at 10 μM identified 4556 compounds (3.9%) as inhibitors. Positive compounds (>50% inhibition) were retested in the assay at 4 inhibitor concentrations. Compounds demonstrating greater than 40% inhibition at 10 μM were considered as confirmed positives, yielding a 68% confirmation rate from the original screen. To eliminate compounds that nonspecifically inhibited glycine uptake, IC50 values were determined in both GlyT1 and GlyT2 assays, and those compounds that inhibited GlyT2 were removed from consideration. The screening campaign identified 300 small molecules as selective GlyT1 inhibitors for lead optimization, demonstrating the utility of this cost-effective method.
ISSN:2472-5552
2472-5560
DOI:10.1177/1087057109347779